Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | SUBITO: IACT vs conventional chemotherapy for HER2-, HRD breast cancer

Sabine Linn • 15 Sep 2024
ESMO 2024
Breast Cancer Olaparib
SUBITO

Sabine Linn, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the results of the Phase III SUBITO trial (NCT02810743) of intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in patients with stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer. Both regimens showed similar 4-year overall survival rates, with no significant difference in recurrence-free survival or pathological complete response. Quality of life was also comparable between treatment arms. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sabine Linn

Stratifying TNBC by TIL levels to tailor treatment approaches
1:39
Stratifying TNBC by TIL levels to tailor treatment approaches
Sabine Linn • 15 Sep 2024
MATADOR: immune gene profiles in tailoring breast cancer treatment
5:53
MATADOR: immune gene profiles in tailoring breast cancer treatment
Sabine Linn • 15 Sep 2024
Exploring the role of olaparib and treatment intensification in high-risk breast cancer
4:41
Exploring the role of olaparib and treatment intensification in high-risk breast cancer
Sabine Linn • 15 Sep 2024
Exploring the role of olaparib and treatment intensification in breast cancer
2:46
Exploring the role of olaparib and treatment intensification in breast cancer
Sabine Linn • 15 Sep 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals